BRIEF published on 12/03/2025 at 11:03, 1 day 19 hours ago Valneva SE : Développements prometteurs dans le domaine du vaccin contre la maladie de Lyme Valneva SE Vaccin Contre La Maladie De Lyme Prévisions Du Marché Pfizer VLA15
BRIEF published on 12/03/2025 at 11:03, 1 day 19 hours ago Valneva SE: Promising Developments in Lyme Disease Vaccine Valneva SE Lyme Disease Vaccine Market Forecast Pfizer VLA15
PRESS RELEASE published on 12/03/2025 at 10:58, 1 day 19 hours ago Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy First Berlin Equity Research updates Buy recommendation for Valneva SE, raising target price to €6.80. VLA15 vaccine progress and market potential analyzed Buy Recommendation Research Update Valneva SE Market Potential VLA15 Vaccine
BRIEF published on 11/04/2025 at 07:05, 1 month ago L'essai de phase 1 de Valneva donne des résultats positifs pour le vaccin contre le Zika Valneva Immunogénicité Essai De Phase 1 Adjuvant Vaccin Contre Le Zika
BRIEF published on 11/04/2025 at 07:05, 1 month ago Valneva's Phase 1 Trial Yields Positive Results for Zika Vaccine Phase 1 Trial Valneva Immunogenicity Zika Vaccine Adjuvant
PRESS RELEASE published on 11/04/2025 at 07:00, 1 month ago Valneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika Vaccine Candidate Valneva SE reports positive Phase 1 trial results for VLA1601, its second-generation Zika vaccine candidate, showing improved immune response. Safety and immunogenicity demonstrated in trial Phase 1 Trial Valneva SE Safety Immunogenicity Zika Vaccine
PRESS RELEASE published on 11/04/2025 at 07:00, 1 month ago Valneva annonce des résultats positifs de Phase 1 pour son candidat vaccin de deuxième génération contre le virus Zika Valneva annonce des résultats positifs de phase 1 pour son candidat vaccin de deuxième génération contre le virus Zika, montrant une réponse immunitaire améliorée Valneva Immunitaire Phase 1 Vaccin Zika
BRIEF published on 10/09/2025 at 16:04, 1 month 26 days ago Franchissement de Seuil par Bpifrance dans le Capital de Valneva SE Franchissement De Seuil Valneva SE Bpifrance Caisse Des Dépôts Marché Actions
BRIEF published on 10/09/2025 at 16:04, 1 month 26 days ago Bpifrance Crosses Threshold in the Capital of Valneva SE Stock Market Valneva SE Threshold Crossing Bpifrance Deposit Fund
PRESS RELEASE published on 10/09/2025 at 15:59, 1 month 26 days ago Franchissement de seuil Déclaration de franchissement de seuil de Bpifrance Participations SA pour VALNEVA SE et CDC, détenant respectivement 4,92% et 7,63% du capital de la société Déclaration Franchissement De Seuil Valneva SE CDC Bpifrance Participations SA
Published on 12/05/2025 at 02:35, 4 hours 3 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 5 hours 38 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 7 hours 33 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours 38 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 03:30, 3 hours 8 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 47 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 13 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 10 hours 23 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 11 hours 28 minutes ago SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance
Published on 12/04/2025 at 18:14, 12 hours 23 minutes ago Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 12 hours 38 minutes ago Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
Published on 12/04/2025 at 18:00, 12 hours 38 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 53 minutes ago Informations relatives au nombre total de droits de vote et d’actions
Published on 12/04/2025 at 17:45, 12 hours 53 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
